Action required: Please refresh your browser
We have recently implemented some changes that require a hard refresh of your browser: Please hold down the CTRL-key and press the F5 key.
After a successful hard refresh, this message should not appear anymore.
More details about this topic are available here »
Cyclerion Therapeutics to Present Clinical Trial Design for CY6463 Phase 2a Study in Participants with Alzheimer’s Disease with Vascular Pathology at the Alzheimer’s Association International Conference 2021 (AAIC) | ||
By: GlobeNewswire - 22 Jul 2021 | Back to overview list |
|
Research to be presented highlighting potential of neuropsychological biomarkers to guide the clinical development of Cyclerion’s investigational therapeutics CAMBRIDGE, Mass., July 22, 2021 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (Nasdaq: CYCN), a clinical-stage biopharmaceutical company on a mission to develop treatments that restore cognitive function, today announced that it will present clinical trial design for a Phase 2a study of its lead development candidate, CY6463, in participants with Alzheimer’s disease with vascular pathology at the upcoming Alzheimer’s Association International Conference 2021 (AAIC). AAIC will be held July 26-30, 2021, virtually and in Denver, CO. In addition, Anna Marin, a researcher in the laboratory of Dr. Andrew Budson and Dr. Katherine Turk in the Department of Neurology, Boston University School of Medicine and Center for Translational and Cognitive Neuroscience, VA Boston Healthcare System, will present results from the Cyclerion sponsored study on peak alpha frequency and N200 latency as predictors of neuropsychological performance in a memory disorders clinic. This pioneering work provides insights into the relationships between electrophysiological measures and cognitive performance in patients with Alzheimer’s disease and other dementias. Cyclerion identified changes in electrophysiological measures in the recent Phase 1 Translational Pharmacology study and will be evaluating electrophysiological and cognitive endpoints in the Phase 2a study in participants with Alzheimer’s disease with vascular pathology. Cyclerion Poster Presentation Details: Title: Clinical trial design for a Phase 2a study evaluating the safety, tolerability, pharmacokinetics, and CNS activity of CY6463 in participants with Alzheimer’s disease with vascular pathology Poster Number: P-54463 Presenter: Chad Glasser, Ph.D., Director of Clinical Research, Cyclerion Therapeutics Authors: Chad Glasser, Jennifer Chickering, Phebe Wilson, Emily Florine, Chris Winrow, Chris Wright The poster presentation will be available beginning at 8 a.m. MT / 10 a.m. ET Monday, July 26, on the AAIC meeting platform. The poster will also be available on the News & Events page of the Cyclerion website https://ir.cyclerion.com/news-events/event-calendar. Center for Translational and Cognitive Neuroscience Poster Presentation Details: Title: Peak alpha frequency and N200 latency as predictors of neuropsychological performance in a memory disorders clinic Poster Number: P-54365 Presenter: Anna Marin B.A., Department of Neurology, Boston University School of Medicine; Center for Translational and Cognitive Neuroscience, VA Boston Healthcare System Authors: Anna Marin B.A.1,2, Kylie Schiloski B.A.2, Naheer Lahdo B.A.2, Ana Vives Rodriguez M.D.2, Renee DeCaro Ph.D.2, Andrew E. Budson M.D.1,2, Katherine W. Turk M.D.1,2 1 Department of Neurology, Boston University School of Medicine; 2Center for Translational and Cognitive Neuroscience, VA Boston Healthcare System The poster presentations will be available beginning at 8 a.m. MT / 10 a.m. ET Monday, July 26, on the AAIC meeting platform. The posters will also be available on the News & Events page of the Cyclerion website https://ir.cyclerion.com/news-events/event-calendar. About Cyclerion Therapeutics For more information about Cyclerion, please visit https://www.cyclerion.com/ and follow us on Twitter (@Cyclerion) and LinkedIn (www.linkedin.com/company/cyclerion). Forward Looking Statement Investors Media
|
||
|
||
Copyright 2021 GlobeNewswire | Back to overview list |